Sankala Group’s Boston Scientific BSX Stock Holding History

Sankala Group’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-166	Closed	-$11.5K	–	630
2026 Q1	$11.5K	Hold	166	–	–	0.01%	364
2025 Q4	$12.8K	Buy	+166	New	+$16.3K	0.01%	357

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sankala Group's BSX Position: Q2 2026 in Review

Sankala Group sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 166 shares — an estimated $11.5K sold.

Sankala Group first reported a position in BSX in Q4 2025 and held it in 2 quarters. The position peaked at $12.8K in Q4 2025. 1,485 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Sankala Group reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Sankala Group sold 166 Boston Scientific shares in Q2 2026, an estimated $11.5K.
Sankala Group first reported a position in Boston Scientific in Q4 2025 and held it in 2 quarters.
Sankala Group's Boston Scientific position peaked at $12.8K in Q4 2025.
1,485 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.